A Placebo-Controlled Study of Collagen Hydrolysate in Subjects With Knee Osteoarthritis (OA) (NMR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00536302
Recruitment Status : Completed
First Posted : September 27, 2007
Last Update Posted : February 6, 2009
Information provided by:

Brief Summary:
This study is designed to evaluate, by MRI, knee cartilage and structure in all subjects. Half the subjects in this study will take collagen hydrolysate each day for 48 weeks and the other half of the subjects will take a placebo dose, that looks like and tastes like the collagen hydrolysate, each day for 48 weeks. MRIs will be taken at Study Weeks -1, 24, and 48.

Condition or disease Intervention/treatment Phase
Knee Osteoarthritis (OA) Dietary Supplement: Collagen Hydrolysate Dietary Supplement: Placebo Phase 2 Phase 3

Detailed Description:
This is a single-site, double-blind, pilot study to evaluate the sensitivity of MRI to detect cartilage structure and composition in subjects taking daily oral collagen hydrolysate (a nutritional supplement) or placebo for 48 weeks. 30 subjects will be randomized to collagen hydrolysate or placebo (1:1 ratio). The goal is to evaluate, by MRI, knee cartilage and structure in all subjects. The primary functional outcome measure will be the WOMAC questionnaire and the primary pathological outcome measure will be knee cartilage structure and composition as measurements done by MRI imaging. Subjects will have contrast dGEMRIC MRIs done at Study Weeks -1, 24 and 48.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Single Center, Prospective, Randomized, Placebo-Controlled, Double-Blind Pilot Clinical Trial to Evaluate the Sensitivity of Magnetic Resonance Imaging to Detect Change in Cartilage Structure and Composition in 30 Participants Diagnosed With Osteoarthritis of the Knee and Treated With Collagen Hydrolysate
Study Start Date : March 2007
Actual Primary Completion Date : November 2008
Actual Study Completion Date : January 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoarthritis
Drug Information available for: Collagen
U.S. FDA Resources

Arm Intervention/treatment
Experimental: 1
Collagen Hydrolysate
Dietary Supplement: Collagen Hydrolysate
Collagen Hydrolysate solution 10 grams per day by mouth for 48 weeks
Placebo Comparator: 2 Dietary Supplement: Placebo
Matching placebo solution per day by mouth for 48 weeks.

Primary Outcome Measures :
  1. To measure the effect of collagen hydrolysate on knee cartilage as measured by MRI. [ Time Frame: 48 Weeks ]

Secondary Outcome Measures :
  1. To measure knee cartilage volume over 48 weeks at three time points. [ Time Frame: 48 Weeks ]
  2. To measure and evaluate WOMAC pain subscale scores over 48 weeks. [ Time Frame: 48 Weeks ]
  3. To evaluate change in physical function tests over 48 weeks. [ Time Frame: 48 Weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   49 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • age > 49 years
  • chronic knee discomfort based on the affirmative response to the question "During the past 6 months, have you had any pain in the knee more than half the days of the month ?"
  • WOMAC pain subscale score ≥ 1
  • tibiofemoral or patellofemoral osteoarthritis on anteroposterior weight-bearing semi-flexed or lateral knee radiographs with at least one osteophyte and no significant joint-space-narrowing
  • clinical examination confirming knee pain or discomfort referable to the knee joint
  • prepared to refrain from use of glucosamine, chondroitin, sAME and doxycycline
  • stable medication and/or supplement use

Exclusion Criteria:

  • use of glucosamine, chondroitin, diacerein or doxycycline within 14 weeks prior to randomization
  • serious medical conditions or impairments that, in the view of the investigator, would obstruct their participation in the trial
  • individuals who are expected not to comply with the study protocol
  • plan to permanently relocate from the region during the trial period
  • planned knee arthroplasty in the study knee
  • active pathology of confounding origin which may cause pain, extending to the knee
  • pregnancy
  • any contra-indication to having an MRI scan

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00536302

United States, Massachusetts
Tufts Medical Center; Center for Arthritis and Rheumatic Diseases
Boston, Massachusetts, United States, 02111
Sponsors and Collaborators
Principal Investigator: Timothy E McAlindon, MD, MPH Tufts Medical Center; Center for Arthritis and Rheumatic Diseases

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Timothy E. McAlindon, MD, MPH - Principal Investigator, Tufts Medical Center Identifier: NCT00536302     History of Changes
Other Study ID Numbers: Gelita TM 1
First Posted: September 27, 2007    Key Record Dates
Last Update Posted: February 6, 2009
Last Verified: February 2009

Keywords provided by GELITA:
Knee arthritis
Nutritional supplement

Additional relevant MeSH terms:
Osteoarthritis, Knee
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases